Clinical Guest Contributors

1. What Is Disease Progression Modeling, And When Is The Right Time To Use It? 10/16/2025

   With the help of Clinical Trials Transformation Initiative's Lindsay Kehoe, discover how disease progression modeling can improve trial efficiency, inform precision medicine, assist in regulatory decision-making, and more.

2. Diverse Enrollment — Ahem, "Biological Variability" — Gets Widespread Support At RAPS Convergence 10/16/2025

   DEI, diverse enrollment, biological variability -- whatever you call it, industry leaders at RAPS Convergence discussed their unwavering support of it when it comes to executing clinical trials that align "good science" with "the right thing to do."

3. Whole-Body MRI Biomarkers Unlock A Fuller Picture In Neuromuscular Trials 10/15/2025

   Discover the utility and promise of whole-body MRIs a digital biomarkers in neuromuscular clinical trials.

4. Trends In Rare Disease Trials: Evaluating Trial Types' Pros, Cons, And Adoption Rates 10/14/2025

   In the second article of the series, Beroe Inc. Lead Analyst Sapna Rani provides a comprehensive evaluation of leading trial types for rare disease development and compares adoption rates, design-specific trade-offs, and practical selection criteria.

5. Trends In Rare Disease Trials: Trial Designs, Challenges, And Regulatory Progress 10/13/2025

   Beroe Inc. Lead Analyst Sapan Rani unpacks the evolution of trial design types in rare disease research, analyzes ongoing challenges, and examines how regulatory support is enabling innovation in part one of this three-part series.

6. How Enveric Biosciences Is Prepping For Its First IND 10/10/2025

   Enveric Biosciences CEO Joseph Tucker, Ph.D., discusses how the team is finalizing IND-enabling studies, leveraging both in-house expertise and trusted external partners.

7. Oncology PI Shares Lessons Learned And Successes Working With Basic Scientists 10/9/2025

   Ranee Mehra, MD, shares her successes and discusses how they shape her approach to future research, as well as details the importance of working closely with basic scientists.

8. Post-Trial Access: Compliance Lessons Hidden In Plain Sight 10/8/2025

   What happens when the trial ends and the investigational product is no longer available? Edye T. Edens, JD, MA, CIP, CCRP, talks through the answer.

9. What Sites Wish Tech Vendors (And Sponsors) Heard At SCDM But Probably Didn't 10/8/2025

   During a Society for Clinical Data Management (SCDM) panel discussion, three site-side representatives discussed the challenges clinical research coordinators have executing their clinical duties amid increasingly complex data entry demands.

10. SCDM 2025: Practical Advice From Global Regulators — Including The FDA 10/6/2025

    Discover what regulators from around the world, including the FDA, think should be top of mind for clinical data managers.